OPKO Health, Inc.
OPK
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $1.2B
$1.64
▲ +1.86%
P/E
-17.62
Mkt Cap
$1.2B
52-Wk Range
$0.98–$1.73
52-Week Range
$0.98 - $1.73
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 15.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Large-scale clinical laboratory network with established physician relationships and recurring revenue base
- Proprietary long-acting therapeutic protein technology platform enabling differentiated drug candidates
- Diversified revenue streams across diagnostics and pharmaceuticals reducing business concentration risk
- International pharmaceutical platforms providing geographic diversification and emerging market exposure
- Integrated diagnostics-pharma model enabling companion diagnostics and clinical trial synergies
Bear Case
1 risk
- Above-average volatility (beta 1.5).
Growth
Stable outlook
Expansion of BioReference Laboratories testing volume driven by aging population and preventive healthcare trends
Value
Deep value opportunity - significant discount to Life Sciences Tools peers
Momentum
Strong
+14.7% over 3m
Quality
Stable
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying OPK right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
JUL 27, 2026
Reported EPS of -$0.01 vs -$0.08 consensus (+87.5% surprise). Revenue of $163.5M vs $131.2M expected (+24.6%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+87.5%
Revenue trend · last 8Q
—
+1%
-14%
-14%
-13%
-19%
-17%
+4%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$173.6M
$183.6M
$150.0M
$156.8M
$151.7M
$148.5M
$124.2M
$163.6M
Margins · last 8Q
Gross
89.5%
Operating
-4.3%
Profit
-5.2%
Wall Street consensus
2 analysts · 50% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
50%
Hold
50%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Jul 29, 2026
vs Industry
How OPK stacks vs Medical - Diagnostics & Research
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related